Investigational drug · Phase 3
TQB2934
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Systemic Light Chain Amyloidosis.
Phase 3Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "TQB2934"
First trial start
2025
Dec 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2934", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Systemic Light Chain Amyloidosis
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2934" as an intervention, largest first.
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaPivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07569757 · 260 participants (planned) · Start Jun 2026 · Primary completion Dec 2028
Drug: TQB2934 injection; Pomalidomide Capsule and 2 more · For: Multiple Myeloma
Sites: Bengbu, China; Hefei, China; Beijing, China · 49 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05646758 · 140 participants (planned) · Start Mar 17, 2023 · Primary completion Oct 2024
Drug: TQB2934 injection · For: Multiple Myeloma
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 7 sites in all
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07266116 · 70 participants (planned) · Start Dec 26, 2025 · Primary completion Feb 2029
Drug: TQB2934 injection · For: Systemic Light Chain Amyloidosis
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 27 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07179679 · 42 participants (planned) · Start Dec 9, 2025 · Primary completion Oct 2027
Drug: TQB2934 injection (subcutaneous injection) · For: Multiple Myeloma
Sites: Chongqing, China; Guangzhou, China; Chengde, China · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.